Woodcock J - Search Results

1

Regulatory watch: What drives differences in review times among CDER divisions?

Schick A, Miller KL, Lanthier M, Woodcock J. Schick A, et al. Among authors: woodcock j. Nat Rev Drug Discov. 2015 Oct;14(10):670-1. doi: 10.1038/nrd4724. Epub 2015 Aug 21. Nat Rev Drug Discov. 2015. PMID: 26294264 No abstract available.

2

Regulation of somatic-cell therapy and gene therapy by the food and drug administration.

Kessler DA, Siegel JP, Noguchi PD, Zoon KC, Feiden KL, Woodcock J. Kessler DA, et al. Among authors: woodcock j. N Engl J Med. 1993 Oct 14;329(16):1169-73. doi: 10.1056/NEJM199310143291607. N Engl J Med. 1993. PMID: 8377782 Free article. Review. No abstract available.

3

The safety of newly approved medicines: do recent market removals mean there is a problem?

Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. Friedman MA, et al. Among authors: woodcock j. JAMA. 1999 May 12;281(18):1728-34. doi: 10.1001/jama.281.18.1728. JAMA. 1999. PMID: 10328074

4

An FDA perspective on the drug development process.

Woodcock J. Woodcock J. Food Drug Law J. 1997;52(2):145-50. Food Drug Law J. 1997. PMID: 10557550 No abstract available.

5

Pharmacogenomic-guided drug development: regulatory perspective.

Lesko LJ, Woodcock J. Lesko LJ, et al. Among authors: woodcock j. Pharmacogenomics J. 2002;2(1):20-4. doi: 10.1038/sj.tpj.6500046. Pharmacogenomics J. 2002. PMID: 11990376 No abstract available.

6

Medical applications of microarray technologies: a regulatory science perspective.

Petricoin EF 3rd, Hackett JL, Lesko LJ, Puri RK, Gutman SI, Chumakov K, Woodcock J, Feigal DW Jr, Zoon KC, Sistare FD. Petricoin EF 3rd, et al. Among authors: woodcock j. Nat Genet. 2002 Dec;32 Suppl:474-9. doi: 10.1038/ng1029. Nat Genet. 2002. PMID: 12454641 Review.

7

Risk management: issues for outcomes research.

Woodcock J. Woodcock J. Value Health. 2003 Jul-Aug;6(4):420-4. doi: 10.1046/j.1524-4733.2003.64004.x. Value Health. 2003. PMID: 12859582 Free article. No abstract available.

8

Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson.

Woodcock J. Woodcock J. Drug Discov Today. 2004 Jul 1;9(13):548-50. doi: 10.1016/S1359-6446(04)03160-5. Drug Discov Today. 2004. PMID: 15203087

9

Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.

Lesko LJ, Woodcock J. Lesko LJ, et al. Among authors: woodcock j. Nat Rev Drug Discov. 2004 Sep;3(9):763-9. doi: 10.1038/nrd1499. Nat Rev Drug Discov. 2004. PMID: 15340386 Review.

10

An audience with... Janet Woodcock discusses the role of the FDA in improving pharma productivity.

Woodcock J. Woodcock J. Nat Rev Drug Discov. 2004 Nov;3(11):904. doi: 10.1038/nrd1570. Nat Rev Drug Discov. 2004. PMID: 15558859 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results